Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Manickam Janakiraman, Efsevia Vakiani, Zhaoshi Zeng, Christine A Pratilas, Barry S Taylor, Dhananjay Chitale, Ensar Halilovic, Manda Wilson, Kety Huberman, Julio Cezar Ricarte Filho, Yogindra Persaud, Douglas A Levine, James A Fagin, Suresh C Jhanwar, John M Mariadason, Alex Lash, Marc Ladanyi, Leonard B Saltz, Adriana Heguy, Philip B Paty Show all
Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2010
Mutations in RAS proteins occur widely in human cancer. Prompted by the confirmation of KRAS mutation as a predictive biomarker of response to epidermal growth factor receptor (EGFR)-targeted therapies, limited clinical testing for RAS pathway mutations has recently been adopted. We performed a multiplatform genomic analysis to characterize, in a nonbiased manner, the biological, biochemical, and prognostic significance of Ras pathway alterations in colorectal tumors and other solid tumor malignancies. Mutations in exon 4 of KRAS were found to occur commonly and to predict for a more favorable clinical outcome in patients with colorectal cancer. Exon 4 KRAS mutations, all of which were ident..View full abstract
Awarded by NATIONAL CANCER INSTITUTE
NIH, the Kimmel Foundation, and the Abrams Foundation. The Memorial Sloan-Kettering Cancer Center Sequenom facility is supported by the Anbinder Fund.